Commonwealth Equity Services LLC Trims Stock Position in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)

Commonwealth Equity Services LLC lowered its holdings in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) by 2.5% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 139,132 shares of the biotechnology company’s stock after selling 3,567 shares during the quarter. Commonwealth Equity Services LLC owned 0.07% of BioCryst Pharmaceuticals worth $1,046,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also modified their holdings of BCRX. BNP Paribas Financial Markets lifted its stake in shares of BioCryst Pharmaceuticals by 472.0% during the 3rd quarter. BNP Paribas Financial Markets now owns 496,784 shares of the biotechnology company’s stock worth $3,776,000 after purchasing an additional 409,938 shares during the period. Principal Financial Group Inc. boosted its holdings in BioCryst Pharmaceuticals by 1,058.1% in the third quarter. Principal Financial Group Inc. now owns 411,414 shares of the biotechnology company’s stock worth $3,127,000 after purchasing an additional 375,890 shares during the period. Cinctive Capital Management LP bought a new stake in shares of BioCryst Pharmaceuticals in the 3rd quarter worth approximately $2,082,000. Two Sigma Advisers LP increased its stake in shares of BioCryst Pharmaceuticals by 13.6% in the third quarter. Two Sigma Advisers LP now owns 2,181,012 shares of the biotechnology company’s stock valued at $16,576,000 after purchasing an additional 261,500 shares during the period. Finally, Exome Asset Management LLC bought a new position in BioCryst Pharmaceuticals in the 3rd quarter valued at about $1,493,000. Institutional investors and hedge funds own 85.88% of the company’s stock.

BioCryst Pharmaceuticals Stock Down 4.6 %

Shares of BioCryst Pharmaceuticals stock opened at $7.50 on Tuesday. BioCryst Pharmaceuticals, Inc. has a 12-month low of $4.03 and a 12-month high of $9.50. The stock has a market cap of $1.57 billion, a P/E ratio of -12.29 and a beta of 1.85. The business’s 50 day moving average is $8.18 and its 200-day moving average is $7.82.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last issued its quarterly earnings data on Monday, February 24th. The biotechnology company reported ($0.13) EPS for the quarter, missing analysts’ consensus estimates of ($0.07) by ($0.06). The business had revenue of $131.50 million during the quarter, compared to analysts’ expectations of $126.64 million. BioCryst Pharmaceuticals’s quarterly revenue was up 40.8% on a year-over-year basis. During the same quarter last year, the company posted $0.28 earnings per share. On average, sell-side analysts expect that BioCryst Pharmaceuticals, Inc. will post -0.36 EPS for the current year.

Analysts Set New Price Targets

A number of equities analysts recently weighed in on the company. Royal Bank of Canada reiterated an “outperform” rating and issued a $11.00 price target (up previously from $10.00) on shares of BioCryst Pharmaceuticals in a research report on Tuesday, February 25th. HC Wainwright reaffirmed a “buy” rating and issued a $30.00 price target on shares of BioCryst Pharmaceuticals in a report on Tuesday, February 25th. Wedbush began coverage on shares of BioCryst Pharmaceuticals in a research report on Tuesday, February 25th. They set an “outperform” rating and a $15.00 target price for the company. Needham & Company LLC lifted their target price on BioCryst Pharmaceuticals from $14.00 to $15.00 and gave the company a “buy” rating in a research note on Monday, January 13th. Finally, Evercore ISI increased their price target on shares of BioCryst Pharmaceuticals from $10.00 to $12.00 and gave the company an “outperform” rating in a research report on Monday, January 13th. One equities research analyst has rated the stock with a hold rating and seven have given a buy rating to the stock. According to MarketBeat, BioCryst Pharmaceuticals has a consensus rating of “Moderate Buy” and a consensus price target of $15.57.

BioCryst Pharmaceuticals Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.